Topic:

M&A

Latest Headlines

Latest Headlines

Reckitt may top Novartis, Sanofi in $12B race for Merck consumer unit

With a final bid deadline looming, Merck & Co.'s consumer health unit still has several big-name pharma suitors. But Reckitt Benckiser, the Irish consumer specialist, may end up snatching the prize, Bloomberg reports.

Sources: Sun to phase out Ranbaxy brand in U.S.

Mention Ranbaxy drugs to some wholesalers and U.S. doctors these days, and they will respond negatively. And so the Ranbaxy brand looks to be on its way out when Sun Pharmaceutical completes its $3.2 billion acquisition of Ranbaxy Laboratories later this year.

TetraLogic bags lymphoma therapy in $13M buyout

Malvern, PA-based TetraLogic is buying up Shape Pharmaceuticals and its Phase II-ready lymphoma gel treatment for $13 million in cash.

Medtronic buys out a distributor as it cozies up to Turkey

Medtronic is looking to bypass some middlemen in its Turkish operation, buying a controlling stake in one of its distributors and launching a joint venture as it works to expand its share of the growing medical device market.

Roche snags diagnostics outfit IQuum in $450M deal

Roche is beefing up its point-of-care molecular diagnostics offerings, signing a deal to acquire Marlborough, MA-based IQuum for $275 million up front and up to $175 million in milestone-based payments.

Charles River wraps up $179M deal for Galapagos' CRO biz

Charles River Laboratories has closed its bid for two CROs formerly owned by drug developer Galapagos, trading $179 million up front and up to $7 million down the line for Argenta and BioFocus.

Mallinckrodt bets $5.6B on Questcor and its controversial Acthar drug

Ireland's Mallinckrodt has been on a major growth spurt since its spinoff last spring from medical device maker Covidien--and it made another big move Monday in its bid to become a major specialty pharma company.

Sun Pharma hopes to turn fortunes of Ranbaxy around with $3.2B buyout

Sun Pharmaceutical has been shopping for deals that would give it more exposure to the U.S. market, and now it has pulled off a stunner. The Indian drugmaker will pay $3.2 million to buy competitor Ranbaxy Laboratories, a company with serious issues but one with big potential in the world's largest market.

AMRI expects its $41M Cedarburg deal to pay off right away

AMRI has wrapped up its $41 million effort to acquire contract manufacturer Cedarburg Pharmaceuticals, and the company says it's in line for an immediate windfall.

Meda spurns Mylan takeover bid

Just four months after closing its $1.75 billion acquisition of Agila Specialities, generic drug maker Mylan is eyeing another takeover candidate--Sweden's Meda AB. Pennsylvania-based Mylan is talking with advisers about a takeover bid that could be made at a "significant premium" to Meda's $4.5 billion market value, according to sources quoted by the Financial Times.